30 JanMT110 recognizes cancer epithelial cells www.acyclovir-info.org/zovirax-cream/.

BiTE antibody MT110 such provide a new class of therapeutic antibodies designed to address the body of the cell-destroying T cells against tumor cells www.acyclovir-info.org/zovirax-cream/ . MT110 recognizes cancer epithelial cells. The cell adhesion molecule, or EpCAM, a target antigen strong and strong and often the surface of many the surface of many types of solid tumors EpCAM has also been shown, in cell culture.ls are expressed, and tumor formation to promote. The data on the AACR show that the antibodies can be directed BiTE MT110 T cells expressing human EpCAM colorectal cells presents to eliminate in cell culture. In addition, data from a study of MT110 in mice showed that the BiTE antibody eliminated even large numbers of implanted cancer stem what. In complete inhibition of tumor growth and survival, while untreated animals with implanted cancer stem cells experienced tumor formation and death – We are excited to see how potently MT110 can act against highly aggressive colorectal cancer stem cells, commented Patrick Baeuerle, Chief Scientific Officer of Micromet. Our new findings are encouraging for the ongoing clinical development of MT110. .

Forward-Looking StatementsThis press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results expressed materially from historical results or from any future results expressed or implied by such forward-looking statements fail. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of MT110. Are encouraged to are encouraged to statements containing the words ongoing, believes, potential, expects, plans, expects, intends, or the negative of consider include these words or other similar words included, as uncertain and forward-looking. Among the factors that could cause actual results expressed from any future results expressed or implied by any forward-looking statements may include risk, clinical trial, is promising in early research appeared, preclinical studies or may not be, any safety and / or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be in further analysis detailed results of such research, preclinical studies or clinical trial, additional confirmed that additional information relating to the safety, efficacy or tolerability of our product candidates may be on a further analysis of preclinical or clinical data, the risk that we or our employees for any permission our product candidates, the risks associated with reliance on outside investors to satisfy market related, and that are discovered risks with with relying on staff, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. As a result. Are more fully discussed in Micromet’s Annual Report on Form 10 – K the 31st for the year ended December 2008 with the SEC on 16 Filed March 2009, and filings with filings with the SEC. Micromet assumes no obligation to update publicly any forward-looking statements, whether as a result. New information, future events or otherwise.

zovirax cream over the counter

Shire of velaglucerase alfa program included the largest and comprehensive set of stage III studies performed to date for Gaucher. Over 100 patients in 24 locations in 10 countries over the world in the clinical studies in the clinical trials.

zovirax cream reviews

Shire , of the the world biopharmaceutical company specializing, today announced it one MAA lodged the European Medicines Agency of velaglucerase alfa, the enterprise enzyme substitution therapy in the development the treating type 1 Gaucher diseases. It is the third application for authorization for of velaglucerase alfa the has been submitted, with previous entry in the U.S. And Canadian.